Drugs / ORH-2014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03048344 | Dec 2016 → Feb 2019 | hematologic disorder | Orsenix LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORH-2014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03048344 ↗ |
| Known as | arsenic trioxide | “ORH-2014 is a novel, oral arsenic trioxide formulation” PMID 31558670 ↗ Sep 2019 |
| Route | Oral | “Twelve patients received ORH-2014 at 5 mg (n=3), 10 mg (n=6), or 15 mg (n=3) orally once a day (fasted state).” PMID 31558670 ↗ Sep 2019 |